RJA
KPTI icon

Raymond James & Associates’s Karyopharm Therapeutics KPTI Stock Holding History

Raymond James & Associates’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-762
Closed -$153K – 3636
2018
Q1 		$153K Sell
762
-554
-42% -$110K ﹤0.01% 3207
2017
Q4 		$189K Buy
1,316
+116
+10% +$18.6K ﹤0.01% 3081
2017
Q3 		$198K Sell
1,200
-1,345
-53% -$193K ﹤0.01% 3050
2017
Q2 		$345K Buy
2,545
+1,156
+83% +$171K ﹤0.01% 2642
2017
Q1 		$267K Buy
+1,389
New +$223K ﹤0.01% 2765

Other funds holding KPTI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Raymond James & Associates's KPTI Position: Q2 2018 in Review

Raymond James & Associates sold out of Karyopharm Therapeutics (KPTI) in Q2 2018, closing a stake of 762 shares — an estimated $153K sold.

Raymond James & Associates first reported a position in KPTI in Q1 2017 and held it in 5 quarters. The position peaked at $345K in Q2 2017. 108 funds tracked by Wall St. Rank hold KPTI as of Q2 2018.

  • Raymond James & Associates reported no remaining Karyopharm Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Raymond James & Associates sold 762 Karyopharm Therapeutics shares in Q2 2018, an estimated $153K.
  • Raymond James & Associates first reported a position in Karyopharm Therapeutics in Q1 2017 and held it in 5 quarters.
  • Raymond James & Associates's Karyopharm Therapeutics position peaked at $345K in Q2 2017.
  • 108 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2018.

Based on Raymond James & Associates's 13F filing for Q2 2018, filed 14 Aug 2018.